Sort:
Date
Filter:
All

1,639 result(s) found

IWMY: That Yield Is Too Good To Be True https://seekingalpha.com/article/4699073-iwmy-that-yield-is-too-good-to-be-true?source=feed_tag_etf_portfolio_strategy Jun 13, 2024 -
Wall Street Analysts Think Archer Aviation (ACHR) Is a Good Investment: Is It? https://www.zacks.com/stock/news/2287805/wall-street-analysts-think-archer-aviation-achr-is-a-good-investment-is-it?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2287805 Jun 13, 2024 - According to the average brokerage recommendation (ABR), one should invest in Archer Aviation (ACHR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Wall Street Analysts Think Vistra (VST) Is a Good Investment: Is It? https://www.zacks.com/stock/news/2287804/wall-street-analysts-think-vistra-vst-is-a-good-investment-is-it?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2287804 Jun 13, 2024 - Based on the average brokerage recommendation (ABR), Vistra (VST) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Wall Street Analysts Think Fiverr (FVRR) Is a Good Investment: Is It? https://www.zacks.com/stock/news/2287811/wall-street-analysts-think-fiverr-fvrr-is-a-good-investment-is-it?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2287811 Jun 13, 2024 - Based on the average brokerage recommendation (ABR), Fiverr (FVRR) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
KLA (KLAC) Is Considered a Good Investment by Brokers: Is That True? https://www.zacks.com/stock/news/2287810/kla-klac-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2287810 Jun 13, 2024 - The average brokerage recommendation (ABR) for KLA (KLAC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
What Makes Cadeler (CDLR) a Good Fit for 'Trend Investing' https://www.zacks.com/stock/news/2287714/what-makes-cadeler-cdlr-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2287714 Jun 13, 2024 - Cadeler (CDLR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
IEA's Monthly Oil Market Report: These Are the Key Takeaways https://www.zacks.com/stock/news/2287820/iea-s-monthly-oil-market-report-these-are-the-key-takeaways?cid=CS-ZC-FT-analyst_blog|industry_focus-2287820 Jun 13, 2024 - Despite IEA's somewhat tepid oil demand view, we believe the space is still a good one for investors to take a position in. We suggest buying stocks like SUN, PUMP and TUWOY.
EVG: A Good Choice For Income, But May Underperform A Regular Bond Fund https://seekingalpha.com/article/4698972-evg-a-good-choice-for-income-but-may-underperform-a-regular-bond-fund?source=feed_tag_etf_portfolio_strategy Jun 12, 2024 - Eaton Vance Short Duration Diversified Income Fund offers high yield, strong price performance, leverage for yield boost. Click for my EVG CEF update.
Snap-on's (SNA) Growth Strategies Seem Good: Apt to Hold? https://www.zacks.com/stock/news/2287491/snap-on-s-sna-growth-strategies-seem-good-apt-to-hold?cid=CS-ZC-FT-analyst_blog|rank_focused-2287491 Jun 12, 2024 - Snap-on's (SNA) performance benefits from strategic initiatives, such as enhancing the franchise network, cost-control efforts and increasing brand awareness.
Cerevel Therapeutics gains after AbbVie says making good progress with FTC https://seekingalpha.com/news/4115228-cerevel-therapeutics-gains-after-abbvie-says-making-good-progress-with-ftc?source=feed_sector_healthcare Jun 12, 2024 - Financial writer reports 1.5% rise in Cerevel Therapeutics (CERE) after Abbvie (ABBV) reaffirms planned acquisition timeline and progress with FTC review.

Pages: 1...6566676869707172737475...164

<<<Page 70>